Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo

Daniela Meco, Tiziana Servidei, Anna Riccardi, Cristiano Ferlini, Gabriella Cusano, Gian Franco Zannoni, Felice Giangaspero, Riccardo Riccardi

Research output: Contribution to journalArticle

Abstract

The effects of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on cell growth and signaling were evaluated in three medulloblastoma (MB) cell lines (D283, D341, Daoy), one supratentorial primitive neuroectodermal tumor cell line (PFSK), and four MB primary cultures. Cell lines showed diverse expression of EGFR and human epidermal receptor 2 (HER2), with high levels of constitutively activated HER2 in the HER2-overexpressing D341 and D283 cells. Gefi-tinib sensitivity varied across lines and was not related to expression of HER receptors or receptor baseline activation. Gefitinib induced G 0/G 1 arrest in all lines, whereas apoptosis was dose-dependently induced only in D283 and D341 cells. The molecular response to gefi-tinib was investigated in Daoy and D341 lines, which showed a higher (half-maximal inhibitory concentration [IC 50], 3.8 μM) and lower (IC 50, 6.6 μM) sensitivity to the agent, respectively. Gefitinib inhibited constitutive and EGF-triggered EGFR phosphorylation in both lines but was ineffective in constitutive activation of HER2 in D341 cells. Phosphorylated AKT inhibition paralleled that of phosphorylated EGFR, suggesting the presence of an autocrine gefitinib-sensitive EGFR/AKT pathway. On the whole, EGF-dependent signaling was less responsive to ligand stimulation and gefitinib inhibition in D341 cells, which correlated with the lower sensitivity to gefitinib's antiproliferative effect of this line. In vivo, the growth of D341 and Daoy xenografts treated with gefitinib at 150 mg/kg per day was inhibited by approximately 50%. Ectopically overexpressed HER2 in Daoy cells significantly increased sensitivity to gefitinib's antitumor effects in vivo (tumor volume inhibition = 78%). Our data indicate that gefitinib might be a molecularly targeted agent for the treatment of MB.

Original languageEnglish
Pages (from-to)250-259
Number of pages10
JournalNeuro-Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Medulloblastoma
Epidermal Growth Factor Receptor
Epidermal Growth Factor
gefitinib
Primitive Neuroectodermal Tumors
Cell Line
Growth
Tumor Burden
Tumor Cell Line
Heterografts
Inhibitory Concentration 50
Phosphorylation
Apoptosis
Ligands

Keywords

  • EGFR
  • Gefitinib
  • HER2
  • In vivo
  • Medulloblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Meco, D., Servidei, T., Riccardi, A., Ferlini, C., Cusano, G., Zannoni, G. F., ... Riccardi, R. (2009). Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro-Oncology, 11(3), 250-259. https://doi.org/10.1215/15228517-2008-095

Antitumor effect in medulloblastoma cells by gefitinib : Ectopic HER2 overexpression enhances gefitinib effects in vivo. / Meco, Daniela; Servidei, Tiziana; Riccardi, Anna; Ferlini, Cristiano; Cusano, Gabriella; Zannoni, Gian Franco; Giangaspero, Felice; Riccardi, Riccardo.

In: Neuro-Oncology, Vol. 11, No. 3, 06.2009, p. 250-259.

Research output: Contribution to journalArticle

Meco, Daniela ; Servidei, Tiziana ; Riccardi, Anna ; Ferlini, Cristiano ; Cusano, Gabriella ; Zannoni, Gian Franco ; Giangaspero, Felice ; Riccardi, Riccardo. / Antitumor effect in medulloblastoma cells by gefitinib : Ectopic HER2 overexpression enhances gefitinib effects in vivo. In: Neuro-Oncology. 2009 ; Vol. 11, No. 3. pp. 250-259.
@article{5d9a739fbb684035ba30b1f959f5785b,
title = "Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo",
abstract = "The effects of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on cell growth and signaling were evaluated in three medulloblastoma (MB) cell lines (D283, D341, Daoy), one supratentorial primitive neuroectodermal tumor cell line (PFSK), and four MB primary cultures. Cell lines showed diverse expression of EGFR and human epidermal receptor 2 (HER2), with high levels of constitutively activated HER2 in the HER2-overexpressing D341 and D283 cells. Gefi-tinib sensitivity varied across lines and was not related to expression of HER receptors or receptor baseline activation. Gefitinib induced G 0/G 1 arrest in all lines, whereas apoptosis was dose-dependently induced only in D283 and D341 cells. The molecular response to gefi-tinib was investigated in Daoy and D341 lines, which showed a higher (half-maximal inhibitory concentration [IC 50], 3.8 μM) and lower (IC 50, 6.6 μM) sensitivity to the agent, respectively. Gefitinib inhibited constitutive and EGF-triggered EGFR phosphorylation in both lines but was ineffective in constitutive activation of HER2 in D341 cells. Phosphorylated AKT inhibition paralleled that of phosphorylated EGFR, suggesting the presence of an autocrine gefitinib-sensitive EGFR/AKT pathway. On the whole, EGF-dependent signaling was less responsive to ligand stimulation and gefitinib inhibition in D341 cells, which correlated with the lower sensitivity to gefitinib's antiproliferative effect of this line. In vivo, the growth of D341 and Daoy xenografts treated with gefitinib at 150 mg/kg per day was inhibited by approximately 50{\%}. Ectopically overexpressed HER2 in Daoy cells significantly increased sensitivity to gefitinib's antitumor effects in vivo (tumor volume inhibition = 78{\%}). Our data indicate that gefitinib might be a molecularly targeted agent for the treatment of MB.",
keywords = "EGFR, Gefitinib, HER2, In vivo, Medulloblastoma",
author = "Daniela Meco and Tiziana Servidei and Anna Riccardi and Cristiano Ferlini and Gabriella Cusano and Zannoni, {Gian Franco} and Felice Giangaspero and Riccardo Riccardi",
year = "2009",
month = "6",
doi = "10.1215/15228517-2008-095",
language = "English",
volume = "11",
pages = "250--259",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Antitumor effect in medulloblastoma cells by gefitinib

T2 - Ectopic HER2 overexpression enhances gefitinib effects in vivo

AU - Meco, Daniela

AU - Servidei, Tiziana

AU - Riccardi, Anna

AU - Ferlini, Cristiano

AU - Cusano, Gabriella

AU - Zannoni, Gian Franco

AU - Giangaspero, Felice

AU - Riccardi, Riccardo

PY - 2009/6

Y1 - 2009/6

N2 - The effects of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on cell growth and signaling were evaluated in three medulloblastoma (MB) cell lines (D283, D341, Daoy), one supratentorial primitive neuroectodermal tumor cell line (PFSK), and four MB primary cultures. Cell lines showed diverse expression of EGFR and human epidermal receptor 2 (HER2), with high levels of constitutively activated HER2 in the HER2-overexpressing D341 and D283 cells. Gefi-tinib sensitivity varied across lines and was not related to expression of HER receptors or receptor baseline activation. Gefitinib induced G 0/G 1 arrest in all lines, whereas apoptosis was dose-dependently induced only in D283 and D341 cells. The molecular response to gefi-tinib was investigated in Daoy and D341 lines, which showed a higher (half-maximal inhibitory concentration [IC 50], 3.8 μM) and lower (IC 50, 6.6 μM) sensitivity to the agent, respectively. Gefitinib inhibited constitutive and EGF-triggered EGFR phosphorylation in both lines but was ineffective in constitutive activation of HER2 in D341 cells. Phosphorylated AKT inhibition paralleled that of phosphorylated EGFR, suggesting the presence of an autocrine gefitinib-sensitive EGFR/AKT pathway. On the whole, EGF-dependent signaling was less responsive to ligand stimulation and gefitinib inhibition in D341 cells, which correlated with the lower sensitivity to gefitinib's antiproliferative effect of this line. In vivo, the growth of D341 and Daoy xenografts treated with gefitinib at 150 mg/kg per day was inhibited by approximately 50%. Ectopically overexpressed HER2 in Daoy cells significantly increased sensitivity to gefitinib's antitumor effects in vivo (tumor volume inhibition = 78%). Our data indicate that gefitinib might be a molecularly targeted agent for the treatment of MB.

AB - The effects of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on cell growth and signaling were evaluated in three medulloblastoma (MB) cell lines (D283, D341, Daoy), one supratentorial primitive neuroectodermal tumor cell line (PFSK), and four MB primary cultures. Cell lines showed diverse expression of EGFR and human epidermal receptor 2 (HER2), with high levels of constitutively activated HER2 in the HER2-overexpressing D341 and D283 cells. Gefi-tinib sensitivity varied across lines and was not related to expression of HER receptors or receptor baseline activation. Gefitinib induced G 0/G 1 arrest in all lines, whereas apoptosis was dose-dependently induced only in D283 and D341 cells. The molecular response to gefi-tinib was investigated in Daoy and D341 lines, which showed a higher (half-maximal inhibitory concentration [IC 50], 3.8 μM) and lower (IC 50, 6.6 μM) sensitivity to the agent, respectively. Gefitinib inhibited constitutive and EGF-triggered EGFR phosphorylation in both lines but was ineffective in constitutive activation of HER2 in D341 cells. Phosphorylated AKT inhibition paralleled that of phosphorylated EGFR, suggesting the presence of an autocrine gefitinib-sensitive EGFR/AKT pathway. On the whole, EGF-dependent signaling was less responsive to ligand stimulation and gefitinib inhibition in D341 cells, which correlated with the lower sensitivity to gefitinib's antiproliferative effect of this line. In vivo, the growth of D341 and Daoy xenografts treated with gefitinib at 150 mg/kg per day was inhibited by approximately 50%. Ectopically overexpressed HER2 in Daoy cells significantly increased sensitivity to gefitinib's antitumor effects in vivo (tumor volume inhibition = 78%). Our data indicate that gefitinib might be a molecularly targeted agent for the treatment of MB.

KW - EGFR

KW - Gefitinib

KW - HER2

KW - In vivo

KW - Medulloblastoma

UR - http://www.scopus.com/inward/record.url?scp=67649628171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649628171&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-095

DO - 10.1215/15228517-2008-095

M3 - Article

C2 - 19033425

AN - SCOPUS:67649628171

VL - 11

SP - 250

EP - 259

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -